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Deleterious mutations in the BRCA1 gene predispose women to an increased risk of breast and ovarian cancer. Many functional
studies have suggested that BRCA1 has a role in DNA damage repair and failure in the DNA damage response pathway often leads
to the accumulation of chromosomal aberrations. Here, we have compared normal lymphocytes with those heterozygous for a
BRCA1 mutation. Short-term cultures were irradiated (8Gy) using a high dose rate and subsequently metaphases were analysed by
24-colour chromosome painting (M-FISH). We scored the chromosomal rearrangements in the metaphases from five BRCA1
mutation carriers and from five noncarrier control samples 6 days after irradiation. A significantly higher level of chromosomal damage
was detected in the lymphocytes heterozygous for BRCA1 mutations compared with normal controls; the average number of
aberrations per mitosis was 3.48 compared with 1.62 in controls (P¼0.0001). This provides new evidence that heterozygous
mutation carriers have a different response to DNA damage compared with noncarriers and that BRCA1 has a role in DNA damage
surveillance. Our finding has implications for treatment and screening of BRCA1 mutation carriers using modalities that involve
irradiation.
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It is estimated that 5–10% of breast cancer patients develop the
disease due to the presence of a highly penetrant breast cancer
predisposition gene. A significant proportion of these patients
(20–45%) have a mutation in the breast cancer genes, BRCA1 or
BRCA2 (Peto et al, 1999). It has long been debated whether
women developing BRCA-associated breast cancer have a different
response to irradiation. This would be clinically important since, if
true, irradiation treatments could lead to more severe acute and
late radiotoxicity and an increased carcinogenic risk for these
individuals. Hence, the optimum management of BRCA1 mutation
carriers remains unclear (Haffty et al, 2002). Elevated chromatid
break frequency and various chromosomal abnormalities in cells
from individuals with many cancer-prone genetic disorders have
been long recognised (reviewed in Eyfjord and Bodvarsdottir,
2005). These abnormalities result from an alteration in chromatin
structure, a higher rate of conversion of double-strand breaks
(DSB) to chromatid breaks or from deficient DNA repair (Radford,
2004). Following DNA damage, cells have a complex response that
may involve cell cycle checkpoint activation, DNA repair mecha-
nisms and programmed cell death (apoptosis). So far, there is
evidence that BRCA1 has a role in all these interdependent events
(Kote-Jarai and Eeles, 1999). BRCA1 is a target for phosphorylation
by ATM, ATR and Chk2 triggered by DNA damage and is required
for cell cycle checkpoint activation (Shiloh, 2003). BRCA1 interacts
with the MRE11-Rad50-NBS1 complex (Zhong et al, 1999), which
is involved in the homologous recombination pathway of DSB
DNA repair. A role for BRCA1 in chromatin remodelling and
activation of transcription have also been described (Bochar et al,
2000).
The phenotypes of cells heterozygous for BRCA1 mutation have
been studied both in vivo and in vitro. Clinical studies of women
with BRCA1 mutations treated with radiation for breast cancer
have not demonstrated increased acute or late toxicity (Pierce,
2005). The in vitro studies, however, are suggestive of differences
between BRCA1 heterozygous cells and controls, but no clear
evidence as yet has emerged for the impaired efficiency of DNA
damage response mechanisms in these cells. Human fibroblasts
and lymphoblastoid cells with heterozygous BRCA1 mutations
seem to have heightened radiosensitivity in some assays (Buchholz
et al, 2002) but not in others (Nieuwenhuis et al, 2002).
Lymphocytes from BRCA1/2 carriers have shown increased
radiosensitivity as measured by cell survival (Rothfuss et al,
2000). Here, we have quantified irradiation-induced chromosome
damage in the lymphocytes of BRCA1 carriers and controls in
order to identify a phenotypic effect of BRCA1 heterozygous
mutations.
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Individuals heterozygous for BRCA1 germline mutations were
identified from the BRCA1 and BRCA2 predictive testing
programme in the Institute of Cancer Research/Royal Marsden
Foundation NHS Trust, Cancer Genetics Carrier Clinic. Fresh
blood samples were collected from five unaffected BRCA1
heterozygous gene mutation carriers and five healthy age-matched
control women with no individual or family history of cancer,
and short-term lymphocyte cultures were established. Written
informed consent was obtained from all participating individuals
prior to inclusion, and the study protocol was approved by the
Royal Marsden Locoregional Ethics Committee. Cells were
cultured for 24h and 6 days following irradiation with 8 Gray
(Gy) at a high dose rate (0.86Gy/min) using a Co
60 source.
Metaphase spreads were prepared according to standard methods
using 50ml colcemid for 2h. Multicolour FISH for karyotyping
was performed using the SpectraVisiont Assay system (Abbott
Laboratories, Maidenhead, UK). SpectraVisiont probes were
hybridised to the chromosome preparations for 48h, then slides
were washed and counterstained with DAPI. Images of metaphase
spreads were captured using a Zeiss epifluorescent microscope
with a six position filter wheel and were analysed using the Quips
SpectraVisiont software (Abbott, as above). An average of 30
metaphases per sample was analysed by an investigator blinded to
the genetic status of the cells. A second cytogeneticist (BS), again
blinded, independently scored a subset of four samples (two
carriers and two controls) to assess interobserver variation. There
was a complete concordance between the observations. Chromo-
somal translocations and breakages were counted per mitosis in
BRCA1 mutation carriers and controls and compared by using the
unpaired Student’s t-test.
RESULTS
In this study, we evaluated a total of 288 metaphases and
chromosomal aberrations were scored per mitosis. At 6 days
postirradiation, aberrations were detected. A representative
metaphase is shown in Figure 1. Analysis of the average number
of aberrations per mitosis revealed an increased level of
chromosomal aberrations in heterozygous BRCA1 mutation
carriers compared with controls. In mutation carriers, the average
number of chromosomal aberrations was 3.4870.24 per mitosis,
whereas in the control samples, this number was 1.6270.33
at 6 days post-irradiation. The difference between controls and
carriers is highly significant, P¼0.0001 (Table 1). All chromo-
somes were equally involved in translocations or breaks when the
data were corrected for chromosomal length. No breakage
‘hotspots’ were identified.
At the earlier time point of 24h post-radiation, based on the
analysis of four samples (two carriers, two controls), we did not
find a difference between BRCA1 mutation carriers and controls.
The number of average chromosome aberrations/mitosis varied
between 0.7 and 2.0 independent of genotype. This suggests that
the substantially higher level of chromosomal damage at 6 days
reflects the heterozygous cells’ lack of ability to recover or
apoptose from irradiation-induced damage. This has not been
previously described.
Our data indicate that after high dose irradiation, lymphocytes
which are heterozygous for a BRCA1 mutation have inefficient
DNA repair and/or apoptotic mechanisms leading to survival of
cells with complex chromosomal aberrations. This observation
confirms the DNA damage surveillance role of BRCA1 and could
also have an impact on the clinical management of patients
carrying a BRCA1 mutation.
DISCUSSION
Our data provide evidence that 6 days after high dose irradiation,
normal cells (lymphocytes) heterozygous for a BRCA1 mutation
develop a significantly higher level of chromosomal aberrations
when compared with controls. Although the 8Gy dose given here
to lymphocytes is higher than that which would be used in a single
screening mammogram or fraction of therapeutic radiation, these
data emphasise that there is a distinct heterozygous phenotype in
normal human cells harbouring a BRCA1 mutation. It is manifest
in the development of twice the number of chromosomal
aberrations after irradiation that is only seen after 6 days and is
not seen acutely (within 24h).
It has been shown that gross chromosomal changes are more
likely to occur in cancers occurring in individuals with germline
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Figure 1 M-FISH analysis of a metaphase spread from a BRCA1 carrier
lymphocyte 6 days after high dose ionizing irradiation (8Gy total). White
arrows show the chromosomal aberrations.
Table 1 Average number of chromosomal aberrations per metaphase in BRCA1 mutation carriers and controls
Sample no. BRCA1 Genotype Aberration/metaphase Sample no. BRCA1 Genotype Aberration/metaphase
1 187_188delAG 3.80 6 Wild type 2.20
2 2313G4T 3.67 7 Wild type 1.60
3 Exon 13 duplication 3.36 8 Wild type 1.39
4 4184_4187delTCAA 3.37 9 Wild type 1.55
5 1014delGT 3.17 10 Wild type 1.40
Average no of aberration/metaphase 3.4870.24 1.6270.33 P¼0.0001
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CGH analysis has identified a pattern of genetic imbalances that
can differentiate familial BRCA1 tumours from unselected sporadic
tumours (van Beers et al, 2005). This indicates that some changes
might be of functional significance in tumour progression or might
represent damage-prone fragile sites.
Recently, it has been shown that BRCA1 is required for common
fragile-site stability. Cells lacking BRCA1 show an increased
expression of specific common fragile sites (Arlt et al, 2004). This
provides further evidence that cells lacking BRCA1 are likely to be
prone to genomic alterations that can lead to deletion of associated
genes and this consequently could promote tumourigenesis.
Our findings might also have some important clinical implica-
tions. It raises the possibility that there may be long-term risks of
the development of chromosomal instabilities after irradiation of
BRCA1 mutation carriers.
Even though the 8Gy dose used in our experimental system
exceeded the 2Gy single fraction size commonly used in a breast
cancer radiotherapy regimes, we have to consider that subsequent
and repeated exposure to radiation might have a long-term and
additive DNA damage effect. Cells with different genetic back-
grounds might respond differently to this. We have used
lymphocytes, rather than breast epithelial cells, in our study as
these are easily collected and the primary aim was to investigate
whether a distinct functional heterozygous phenotype for BRCA1
carriers exists which may lead to the development of a clinically
useful assay. However, there is also experimental evidence
that ionising radiation induces various molecular changes in
breast epithelial cells and that a BRCA1-mutated breast cancer cell
line shows deficient repair and increased chromosomal aberration
(Mamon et al, 2003). We have also previously reported finding a
differential gene expression profile in normal breast fibroblasts
in response to DNA damage between BRCA1 mutation carriers
and controls (Kote-Jarai et al, 2004), supporting the hypothesis
that response to DNA damage due to irradiation differs in BRCA1
mutation carriers. Consequently, we suggest that clinical follow-up
of the screening and treatment of individuals harbouring
BRCA1 mutations is imperative. Studies are urgently needed to
elucidate the applicability of these data to the clinical use of
irradiation in screening and treatment for the management of
BRCA1 gene mutation carriers. Concerns about the potential
mutagenicity of ionising radiation, both radiotherapy and
surveillance mammography in this group, have already driven
the search for alternative tools such as breast magnetic resonance
imaging in the UK MARIBS study (The MARIBS Advisory Group,
2005). Based on cohort studies of long-term mortality and risk
estimation models for the induction of secondary cancers
following radiotherapy at least 15–20 years follow-up will be
required to fully assess whether there is an increased long-term
treatment induced cancer risk (Dasu et al, 2005; Darby et al, 2005)
and subtle late toxicity from irradiation in BRCA1 mutation
carriers.
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